Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMAG’s ferumoxytol gets Dec. 30 PDUFA date

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AMAG hopes to ring in the new year with approval of its anemia product ferumoxytol, recently assigned a Dec. 30, 2008 PDUFA target action date. FDA designated the company's resubmission to an October "complete response" letter as a complete Class 1 response, setting a two month review clock, the firm announced Nov. 13. Ferumoxytol, an intravenous iron replacement agent, is indicated for treatment of iron deficiency anemia in patients with all stages of chronic kidney disease, as well as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease. AMAG aims to launch the drug, which provides quicker administration at higher doses than available I.V. iron products, in the first quarter of next year (1"The Pink Sheet" DAILY, Oct. 20, 2008). A potential rival, Luitpold's Injectafer, has two "not approvable" letters to its name, including one requesting more clinical trials

Related Content

Topics

UsernamePublicRestriction

Register

PS003966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel